Capital (CAPD) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
19 Mar, 2026Executive summary
FY 2025 revenue was $345.8m, essentially flat year-on-year, with a strong rebound in H2 after a weak H1, and MSALABS growth offsetting mining fleet redeployment.
Adjusted EBITDA rose 1.1% to $79.5m, with a margin of 23.0%, and NPAT surged 317.6% to $71.0m, driven by a $66.0m investment gain.
Investment portfolio delivered outstanding returns, valued at $97.5m at year-end, now constituting over a quarter of market capitalization.
Completed a successful capital raise in December/November 2025, strengthening the balance sheet and funding growth initiatives, ending with net debt of $31.8m.
Mining fleet fully utilized following new contracts at Reko Diq (Pakistan) and Sukari Gold Mine (Egypt).
Financial highlights
Adjusted cash from operations increased 20.5% to $92.9m, aided by favorable working capital movements.
Net debt at year-end was $31.8m, with leverage at 0.4x net debt to adjusted EBITDA.
Shareholder equity rose 38.0% to $388.7m.
Dividend maintained for the 12th consecutive year, totaling $0.026 per share for 2025, with a final dividend of 1.3cps declared.
Adjusted EBITDA margin exceeded 25% in H2 2025, near record levels.
Outlook and guidance
2026 revenue guidance set at $410–$440m, representing over 20% year-on-year growth, with MSALABS revenue expected at $85–$95m and CapEx at $55–$65m.
Multiple new long-term contracts announced, including lab and grade control contracts, with strong demand outlook across all business segments.
Management believes the sector is at the front end of a multi-year demand cycle, supported by record client cash flows and robust commodity prices.
Latest events from Capital
- 2023 growth and Tier 1 wins underpin a $355m-$375m revenue target for 2024.CAPD
H2 2023 - Q3 revenue rose 23.2% YoY; 2026 guidance increased to $435–$455m.CAPD
Q3 2026 TU - Revenue up 37.6% and guidance raised, driven by strong contracts and MSALABS growth.CAPD
H1 2026 - Record Q2 revenue and strong outlook, with growth across all divisions and new contracts.CAPD
Q2 2026 TU - Record revenue, 2026 guidance, lab expansion, and strategic growth amid strong demand.CAPD
AGM 2026 - Record Q1 revenue and new contracts drive strong 2026 outlook despite portfolio volatility.CAPD
Q1 2026 TU - Revenue up 9.8%, margins down; growth expected from new contracts and US expansion.CAPD
H1 2024 - 2024 revenue guidance is $355–$375 million, with key resolutions and growth across business pillars.CAPD
AGM 2024 - Record 2024 revenue, with 2025 growth expected as Reko Diq and MSALABS ramp up.CAPD
H2 2024